Ameliorative impacts of polymeric and metallic nanoparticles on cisplatin-induced nephrotoxicity: a 2011-2022 review.
Anti-apoptosis
Antioxidant
Cisplatin
Kidney
Metallic nanoparticles
Nephroprotection
Nephrotoxicity
Polymers
Journal
Journal of nanobiotechnology
ISSN: 1477-3155
Titre abrégé: J Nanobiotechnology
Pays: England
ID NLM: 101152208
Informations de publication
Date de publication:
01 Dec 2022
01 Dec 2022
Historique:
received:
05
09
2022
accepted:
22
11
2022
entrez:
2
12
2022
pubmed:
3
12
2022
medline:
6
12
2022
Statut:
epublish
Résumé
Cisplatin (CDDP) is a well-known platinum-based drug used in the treatment of various malignancies. However, the widespread side effects that this drug leaves on normal tissues make its use limited. Since cisplatin is mainly eliminated from the kidneys, CDDP-induced nephrotoxicity is the most significant dose-limiting complication attributed to cisplatin, which often leads to dose withdrawal. Considering the high efficiency of cisplatin in chemotherapy, finding renoprotective drug delivery systems for this drug is a necessity. In this regard, we can take advantages of different nanoparticle-based approaches to deliver cisplatin into tumors either using passive targeting or using specific receptors. In an effort to find more effective cisplatin-based nano-drugs with less nephrotoxic effect, the current 2011-2022 review study was conducted to investigate some of the nanotechnology-based methods that have successfully been able to mitigate CDDP-induced nephrotoxicity. Accordingly, although cisplatin can cause renal failures through inducing mitochondria dysfunction, oxidative stress, lipid peroxidation and endoplasmic reticulum stress, some CDDP-based nano-carriers have been able to reverse a wide range of these advert effects. Based on the obtained results, it was found that the use of different metallic and polymeric nanoparticles can help renal cells to strengthen their antioxidant systems and stay alive through reducing CDDP-induced ROS generation, inhibiting apoptosis-related pathways and maintaining the integrity of the mitochondrial membrane. For example, nanocurcumin could inhibit oxidative stress and acting as a ROS scavenger. CONPs could reduce lipid peroxidation and pro-inflammatory cytokines. CDDP-loaded silver nanoparticles (AgNPs) could inhibit mitochondria-mediated apoptosis. In addition, tea polyphenol-functionalized SeNPs (Se@TE) NPs could mitigate the increased level of dephosphorylated AKT, phosphorylated p38 MAPK and phosphorylated c-Jun N-terminal kinase (JNK) induced by cisplatin. Moreover, exosomes mitigated cisplatin-induced renal damage through inhibiting Bcl2 and increasing Bim, Bid, Bax, cleaved caspase-9, and cleaved caspase-3. Hence, nanoparticle-based techniques are promising drug delivery systems for cisplatin so that some of them, such as lipoplatins and nanocurcumins, have even reached phases 1-3 trials.
Identifiants
pubmed: 36457031
doi: 10.1186/s12951-022-01718-w
pii: 10.1186/s12951-022-01718-w
pmc: PMC9714065
doi:
Substances chimiques
Cisplatin
Q20Q21Q62J
Polymers
0
Reactive Oxygen Species
0
Silver
3M4G523W1G
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
504Informations de copyright
© 2022. The Author(s).
Références
Biol Trace Elem Res. 2022 Sep;200(9):4017-4026
pubmed: 34719747
Antioxidants (Basel). 2019 Oct 09;8(10):
pubmed: 31600935
Nutr Neurosci. 2012 Sep;15(5):34-41
pubmed: 22776704
Kidney Int. 2008 May;73(9):994-1007
pubmed: 18272962
Toxicol Lett. 2016 Jan 5;240(1):105-13
pubmed: 26546572
Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14298-302
pubmed: 12370430
J Control Release. 2011 Jul 15;153(1):64-72
pubmed: 21497174
Int J Pharm. 2014 Dec 30;477(1-2):261-72
pubmed: 25455774
Am J Physiol Cell Physiol. 2005 Dec;289(6):C1466-75
pubmed: 16107504
Eur J Drug Metab Pharmacokinet. 2019 Apr;44(2):169-177
pubmed: 30328058
Anticancer Agents Med Chem. 2007 Jan;7(1):3-18
pubmed: 17266502
Acta Biomater. 2015 May;18:68-76
pubmed: 25707922
Kidney Int. 2004 Jul;66(1):196-202
pubmed: 15200426
J Bioenerg Biomembr. 2007 Feb;39(1):43-50
pubmed: 17318397
Ir Med J. 2002 May;95(5):145-6, 148
pubmed: 12092697
Pharmaceuticals (Basel). 2021 May 21;14(6):
pubmed: 34063951
Biomed Pharmacother. 2009 Feb;63(2):79-85
pubmed: 18819770
Biomaterials. 2014 Aug;35(24):6462-72
pubmed: 24797881
Pharmaceutics. 2021 Dec 27;14(1):
pubmed: 35056952
Sci Rep. 2017 Jul 5;7(1):4636
pubmed: 28680107
Front Pharmacol. 2018 Sep 27;9:1111
pubmed: 30319427
Invest New Drugs. 2000 Aug;18(3):281-9
pubmed: 10958599
Urol J. 2020 Apr 30;18(3):295-300
pubmed: 32350847
Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6656-61
pubmed: 21464325
Mater Sci Eng C Mater Biol Appl. 2014 May 1;38:85-93
pubmed: 24656356
Eur J Pharm Biopharm. 2008 Mar;68(3):503-12
pubmed: 17881198
PLoS One. 2012;7(10):e47562
pubmed: 23082177
Antioxidants (Basel). 2018 Jul 24;7(8):
pubmed: 30042320
Kidney Int. 2014 Mar;85(3):547-60
pubmed: 24025646
Nanomedicine. 2019 Jan;15(1):153-163
pubmed: 30308299
J Biomed Nanotechnol. 2016 Apr;12(4):656-66
pubmed: 27301192
Kidney Int. 2003 Jan;63(1):72-82
pubmed: 12472770
Int J Biol Macromol. 2015 Jan;72:1313-22
pubmed: 25450550
Pharm Dev Technol. 2019 Oct;24(8):927-934
pubmed: 30526167
Clin Cancer Res. 2017 Dec 1;23(23):7312-7323
pubmed: 28912139
Biomater Sci. 2020 Oct 21;8(20):5698-5714
pubmed: 32930254
Chem Rev. 2016 Mar 9;116(5):3436-86
pubmed: 26865551
J Clin Oncol. 1999 Jan;17(1):409-22
pubmed: 10458260
Am J Physiol Renal Physiol. 2019 Nov 1;317(5):F1255-F1264
pubmed: 31532243
Crit Rev Ther Drug Carrier Syst. 2013;30(3):257-76
pubmed: 23614648
Toxins (Basel). 2010 Nov;2(11):2490-518
pubmed: 22069563
Adv Healthc Mater. 2015 May;4(7):1066-75
pubmed: 25656800
Int J Nanomedicine. 2012;7:2557-71
pubmed: 22745537
Toxicol Lett. 2010 Nov 10;199(1):80-92
pubmed: 20732396
Toxicol Appl Pharmacol. 2019 Oct 1;380:114704
pubmed: 31400413
Acta Pharmacol Sin. 2021 Dec;42(12):1951-1969
pubmed: 33750909
Drug Discov Today. 2012 Jan;17(1-2):71-80
pubmed: 21959306
J Am Soc Nephrol. 2003 Jan;14(1):1-10
pubmed: 12506132
J Appl Toxicol. 2014 Jan;34(1):25-32
pubmed: 22987311
Biochim Biophys Acta. 1985;780(3):167-80
pubmed: 3896310
Nat Rev Nephrol. 2016 Dec;12(12):738-753
pubmed: 27795549
Exp Mol Med. 2006 Aug 31;38(4):393-400
pubmed: 16953118
RSC Adv. 2018 Jun 22;8(41):22967-22973
pubmed: 35540171
Drug Chem Toxicol. 2019 Jan;42(1):94-103
pubmed: 30203673
Polymers (Basel). 2021 May 30;13(11):
pubmed: 34070811
Exp Toxicol Pathol. 2009 May;61(3):223-42
pubmed: 18986801
Mol Pharm. 2007 Nov-Dec;4(6):807-18
pubmed: 17999464
Cancer Res. 1986 Apr;46(4 Pt 2):1972-9
pubmed: 3512077
Am J Physiol. 1990 May;258(5 Pt 2):F1181-7
pubmed: 2159714
Int J Nanomedicine. 2020 Feb 12;15:981-990
pubmed: 32103951
Biochim Biophys Acta Mol Basis Dis. 2020 Dec 1;1866(12):165911
pubmed: 32768679
Biol Trace Elem Res. 2019 May;189(1):145-156
pubmed: 30047078
Acta Biomater. 2019 Jul 1;92:205-218
pubmed: 31071475
Biomaterials. 2014 May;35(14):4297-309
pubmed: 24565522
Int J Immunopathol Pharmacol. 2021 Jan-Dec;35:20587384211066441
pubmed: 34915755
Int J Biochem. 1994 Aug;26(8):1009-16
pubmed: 8088411
RSC Adv. 2022 May 16;12(23):14808-14818
pubmed: 35702211
Surgery. 2013 Nov;154(5):991-9
pubmed: 24008088
Yao Xue Xue Bao. 2007 Apr;42(4):376-80
pubmed: 17633203
Clin Exp Nephrol. 2012 Dec;16(6):843-51
pubmed: 22569819
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):3212-3221
pubmed: 31359793
Am J Pathol. 2005 Dec;167(6):1477-84
pubmed: 16314463
Pharmacol Rev. 1999 Dec;51(4):691-743
pubmed: 10581328
Int J Mol Sci. 2021 Jan 13;22(2):
pubmed: 33450917
ACS Appl Mater Interfaces. 2018 Oct 3;10(39):33060-33069
pubmed: 30204401
Expert Opin Pharmacother. 2003 Jun;4(6):889-901
pubmed: 12783586
Biochem Pharmacol. 1994 Aug 3;48(3):453-9
pubmed: 8068032
Int J Pharm. 2022 Nov 25;628:122268
pubmed: 36209978
Int J Pharm. 2022 Oct 15;626:122161
pubmed: 36058409
J Ayurveda Integr Med. 2020 Jan - Mar;11(1):24-36
pubmed: 30115410
Int J Nanomedicine. 2013;8:2399-407
pubmed: 23861585
J Control Release. 2022 May;345:709-720
pubmed: 35367476
Nat Rev Drug Discov. 2005 Apr;4(4):307-20
pubmed: 15789122
Colloids Surf B Biointerfaces. 2019 Dec 1;184:110465
pubmed: 31546222
Naunyn Schmiedebergs Arch Pharmacol. 2020 Sep;393(9):1581-1598
pubmed: 32458010
Chem Biol Interact. 2011 Jan 15;189(1-2):45-51
pubmed: 21044617
Pak J Pharm Sci. 2020 Mar;33(2(Supplementary)):787-793
pubmed: 32863253
Naunyn Schmiedebergs Arch Pharmacol. 2020 Dec;393(12):2411-2425
pubmed: 32710137
J Pharm Pharm Sci. 2012;15(1):112-23
pubmed: 22365093
Cell Death Differ. 2006 Mar;13(3):363-73
pubmed: 16397583
Mutat Res Genet Toxicol Environ Mutagen. 2014 Aug;770:23-8
pubmed: 25344160
Toxicol Lett. 2008 Jan 4;176(1):48-57
pubmed: 18063323
Science. 1998 Aug 28;281(5381):1309-12
pubmed: 9721092
Aging (Albany NY). 2020 Sep 23;12(18):18008-18018
pubmed: 32965241
J Pharmacol Exp Ther. 2002 Jan;300(1):142-8
pubmed: 11752109
Mol Pharm. 2019 Sep 3;16(9):3957-3967
pubmed: 31381352
Bioorg Med Chem. 2006 Jan 1;14(1):138-42
pubmed: 16182539
Naunyn Schmiedebergs Arch Pharmacol. 2020 Oct;393(10):1941-1953
pubmed: 32447466
J Mater Chem B. 2013 Dec 14;1(46):6365-6372
pubmed: 32261335
Apoptosis. 2008 Jan;13(1):11-32
pubmed: 17968659
Acta Biomater. 2015 May;18:132-43
pubmed: 25735801
Chem Rev. 2009 Oct;109(10):4911-20
pubmed: 19711978
Cancer Res. 1973 Jun;33(6):1310-5
pubmed: 4515709
J Pharmacol Exp Ther. 2003 Jun;305(3):1183-90
pubmed: 12649298
Pharmacol Res. 2017 Mar;117:218-227
pubmed: 28042086
Acta Pharm Sin B. 2020 Jun;10(6):1106-1121
pubmed: 32642416
Oncol Rep. 2013 Apr;29(4):1285-92
pubmed: 23404427
IUBMB Life. 2020 Sep;72(9):1930-1940
pubmed: 32542981
Biol Trace Elem Res. 2022 Feb;200(2):582-590
pubmed: 33759109
Life Sci. 2015 Dec 1;142:76-85
pubmed: 26482203
Nano Lett. 2018 Jul 11;18(7):4618-4625
pubmed: 29902013
Kidney Int. 2004 Feb;65(2):490-9
pubmed: 14717919
Eur J Pharmacol. 2014 Oct 5;740:364-78
pubmed: 25058905
Chem Soc Rev. 2013 Jan 7;42(1):202-24
pubmed: 23042411
J Control Release. 2002 Feb 19;79(1-3):123-35
pubmed: 11853924
Int J Oncol. 2015 Mar;46(3):1268-74
pubmed: 25544240